Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) announced that CEO Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during SAGES NBT Innovation Weekend, Feb 19-21, 2026, in Houston.

The session Endovascular Therapeutics: AI and Robotics will showcase the LIBERTY Endovascular Robotic System, its single-use remote operation, and planned full market release at SIR in April 2026.

Market Reality Check

Price: $2.10 Vol: Volume 1,507,700 is below...

low vol

$2.10 Last Close

Volume Volume 1,507,700 is below the 2,638,700 share 20-day average (relative volume 0.57). low

Technical Price 2.1 is trading below the 200-day moving average at 2.59, after a -0.94% day.

Peers on Argus

Momentum scanner shows one peer up (ZTEK +4.26%) and one down (STSS -5.59%), sug...

1 Up 1 Down

Momentum scanner shows one peer up (ZTEK +4.26%) and one down (STSS -5.59%), suggesting mixed moves rather than a coordinated sector trend around this news.

Historical Context

5 past events · Latest: Feb 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Conference visibility	Positive	+4.5%	LIBERTY showcased at major vascular disease management conference, reinforcing market launch plans.
Feb 05	Conference showcase	Positive	-6.9%	LIBERTY exposure at oncology meeting to support adoption during limited market release.
Jan 12	Milestones update	Positive	+1.9%	Reported 2025 progress, pivotal data, and 2026 commercial milestones for LIBERTY.
Nov 26	First hospital adoption	Positive	+21.8%	Emory University Hospital became first clinical adopter and partner for robotics program.
Nov 05	Limited U.S. launch	Positive	+5.0%	Announced U.S. commercial availability via Limited Market Release after 510(k) clearance.

Pattern Detected

News on LIBERTY’s commercialization and conference visibility has usually led to positive price moves, with one notable negative divergence.

Recent Company History

Over the past months, Microbot Medical has repeatedly highlighted its LIBERTY® Endovascular Robotic System’s transition from development to commercialization. Updates included FDA 510(k) clearance, the start of a Limited Market Release in late 2025, and Emory University Hospital as the first adopter. Conference-focused visibility at ISET and other meetings emphasized LIBERTY’s single-use, remotely operated design and peripheral endovascular indication, ahead of a planned full market release at SIR in April 2026. Most of these visibility and commercialization milestones produced positive 24-hour price reactions, with one negative outlier.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active Form S-3/A shelf registration filed on 2025-10-28, described as Amendment No. 1 to its S-3. The filing added Rule 473(b) language for automatic effectiveness and listed total issuance and distribution expenses of $25,000.00, including an SEC fee of $404.02. Subsequent usage is evidenced by two 424B3 prospectus filings on 2025-11-19, indicating the shelf has been tapped for registered resale activity.

Market Pulse Summary

This announcement highlights continued visibility for the LIBERTY® Endovascular Robotic System as Mi...

Analysis

This announcement highlights continued visibility for the LIBERTY® Endovascular Robotic System as Microbot Medical participates in an innovation-focused surgical conference, emphasizing endovascular therapeutics, AI, and robotics. It reinforces LIBERTY’s positioning as an FDA-cleared, single-use, remotely operated system for peripheral endovascular procedures and echoes previous milestones around its Limited Market Release and planned full launch at SIR in April 2026. Investors may watch adoption trends, additional regulatory filings, and further conference feedback as commercialization progresses.

Key Terms

endovascular, ai, robotics, fda cleared, +2 more

6 terms

endovascular medical

"with a Special Focus on the Endovascular Space"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

ai technical

"A dedicated panel, titled Endovascular Therapeutics: AI and Robotics"

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

robotics technical

"A dedicated panel, titled Endovascular Therapeutics: AI and Robotics"

Robotics is the design, building and programming of machines that can perform physical tasks autonomously or with minimal human control, ranging from simple mechanical helpers to complex intelligent systems. For investors, robotics matters because these machines can boost productivity, cut operating costs, and create new markets much like adding a team of tireless, precise workers; companies that develop or adopt robotics can gain competitive advantages and shift future revenue and expenses.

fda cleared regulatory

"LIBERTY is the only FDA cleared, single-use, remotely operated robotic system"

FDA cleared means the U.S. Food and Drug Administration reviewed a medical device and agreed it is similar enough to an already allowed product to be marketed in the United States. Think of it like a new car model using largely the same, proven parts as an earlier model — the regulator gives a green light for sales but does not imply the more extensive testing required for full approval. For investors, clearance signals regulatory access to the U.S. market and typically lowers commercialization risk compared with no clearance.

peripheral endovascular procedures medical

"remotely operated robotic system for peripheral endovascular procedures"

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

radiation exposure medical

"designed for precise vascular navigation while aiming to reduce radiation exposure"

Radiation exposure is the amount of ionizing energy from sources like X-rays, medical treatments, industrial equipment, or nuclear materials that people, products, or environments receive; think of it like sun exposure but from invisible high-energy rays that can damage cells over time. Investors care because excessive exposure can trigger health risks, regulatory fines, facility shutdowns, cleanup costs and liability claims, all of which can affect a company’s operations, reputation and financial outlook.

AI-generated analysis. Not financial advice.

Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of the Next Decade with a Special Focus on the Endovascular Space

HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES’s mission is to innovate, educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend serves as an open forum for dialogue between industry and providers on innovations in surgical technology and surgical practice.

Industry thought leaders, including robotic pioneers, will discuss advancing technologies with a focus on minimally invasive and less invasive interventions. A dedicated panel, titled Endovascular Therapeutics: AI and Robotics, will provide Mr. Gadot with a platform to highlight the unique features of the LIBERTY System, allowing the Company to establish a new category of surgical robotics. The Company believes that the growing confidence in AI and robotic innovations in endovascular procedures can support the accelerated adoption of LIBERTY. These innovations include remote interventions, precision navigation, and catheter-based robotics designed to enhance access, safety, and clinical outcomes across vascular care.

“We believe that the continued emergence of the LIBERTY System, together with the expanding range of procedures performed to date, is redefining how endovascular care is delivered today and how it will be delivered years ahead,” commented Mr. Gadot. “The dedicated session around the Endovascular space serves as another proof of the opportunities it holds. LIBERTY’s distinct advantages, including its single-use, compact robotic design, are intended to remove many of the barriers that have historically limited the broader adoption of surgical robotics. We believe this positions LIBERTY as a new class of surgical robotics, expanding access to advanced robotics and enabling high quality care for a broader range of health systems and patients.”

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What is Microbot Medical (MBOT) presenting at SAGES NBT Innovation Weekend Feb 19-21, 2026?

Microbot Medical will highlight the LIBERTY Endovascular Robotic System in an endovascular AI and robotics panel. According to the company, CEO Harel Gadot is a featured panelist and will discuss LIBERTY's single-use, compact, remotely operated design and clinical use cases.

When does Microbot Medical (MBOT) plan a full market release of the LIBERTY system?

Microbot Medical plans a full market release of LIBERTY at the Society of Interventional Radiology conference in April 2026. According to the company, this follows a limited market release that began in late 2025 and aims to deepen market adoption.

What distinguishes the LIBERTY system that Microbot Medical (MBOT) will emphasize at the conference?

LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. According to the company, it targets precise vascular navigation while reducing radiation exposure and operator strain.

How does Microbot Medical (MBOT) say LIBERTY could affect adoption of surgical robotics?

The company says LIBERTY's single-use, compact design is intended to lower barriers to robotic adoption across health systems. According to the company, remote interventions and precision navigation could expand access and clinical use of endovascular robotics.

Who will represent Microbot Medical (MBOT) at the Endovascular Therapeutics: AI and Robotics panel?

Harel Gadot, CEO, President and Chairman of Microbot Medical, will be a featured panelist at the session. According to the company, he will highlight LIBERTY's features and discuss endovascular robotics and AI trends with industry leaders.

What procedural benefits does Microbot Medical (MBOT) attribute to the LIBERTY system?

The company cites potential benefits including enhanced access, improved safety, and precise catheter navigation in vascular care. According to the company, LIBERTY aims to reduce radiation exposure and physical strain during peripheral endovascular procedures.